About the Ypsomed Group

The Ypsomed Group is the leading developer and manufacturer of injection and infusion systems for self-
medication and a renowned diabetes specialist with over 30 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1 700 employees.

Ypsomed Diabetes Care

With its mylife™ Diabetescare brand, Ypsomed operates successfully in the B2C business with products and services for people with diabetes mellitus. The product portfolio includes: insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and other diabetes supplies. Products are distributed via Ypsomed’s subsidiaries to hospitals, doctors, pharmacies and patients, and via distributors (pen needles).

Diabetes: A global disease with pandemic growth predicted in the coming 20 years. Currently diabetes is growing at approximately 9 % p. a. Due to that fact Ypsomed is expanding its network of subsidiaries consequently with its outstanding product portfolio.

Ypsomed Delivery Systems

Our pharmaceutical and biotech customers purchase injection systems and corresponding services under the YDS brand, Ypsomed Delivery Systems. They do this via the industry leader, as Ypsomed is the world’s largest developer and manufacturer of pens and autoinjectors with which patients can administer their liquid medication subcutaneously themselves.

Trends for future drugs: Drugs are becoming more specific, e.g. in the treatment of autoimmune diseases. Instead of a generic drug (e.g. Humira®), a large number of new, very specific drugs come onto the market. New drugs for Alzheimer's disease, obesity and rare diseases are being developed. Cancer drugs are also becoming more specific. Efforts to develop active ingredients for subcutaneous injection open up opportunities for self-medication with auto- and patch injectors.

Financials

Especially due to the uncertainty surrounding the start of new users on insulin pumps, it is difficult to provide a reliable outlook for the group. In the coming months, we will continue to analyse the situation and evaluate what we can learn from this exceptional situation and what further opportunities it presents for us. For the financial year 2020/21 we expect a growth in turnover and an increase in profitability. From today’s perspective, we still consider our medium-term EBIT target of CHF 100 million to be achievable.

Development of turnover and EBIT Ypsomed Group - 2019/20

Financial key figures 2019/20

In thousand CHF

  01 April 2019 –
31 March 2020
in % 01 April 2018 –
31 March 2019
in % thereof
discontinued
operation
thereof
continued
operations
Sales of goods and services group 393 866 100.0 % 453 765 100.0 % 100 944 352 821
Ypsomed Diabetes Care 187 309 47.6 % 280 425 61.8 % 100 944 179 481
Ypsomed Delivery Systems 192 032 48.8 % 155 730 34.3 %   155 730
Others 14 526 3.7 % 17 610 3.9 %   17 610
Operating profit group 9 289 2.4 % 73 344 16.2 % 61 896 11 448
             
Financial income 4 417 1.1 % 3 197 0.7 %    
Financial expenses – 6 250 – 1.6 % – 6 660 – 1.5 %    
Income taxes 3 996 1.0 % – 9 744 – 2.1 %    
Net profit 11 452 2.9 % 60 136 13.3 %    
             
Earnings per share in CHF 0.91   4.77      
             
Operating profit 9 289   73 344      
Depreciation and impairment of fixed assets 30 365   25 747      
Amortisation and impairment of
intangible assets
22 434   19 141      
EBITDA (Operating profit before depreciation
and amortisation)
62 088 15.8 % 118 232 26.1 %